Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Certuity LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 637 shares of the biopharmaceutical company’s stock after selling 1,536 shares during the period. Certuity LLC’s holdings in Regeneron Pharmaceuticals were worth $492,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Torren Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $38,000. M&T Bank Corp lifted its holdings in Regeneron Pharmaceuticals by 20.5% in the 4th quarter. M&T Bank Corp now owns 6,435 shares of the biopharmaceutical company’s stock worth $4,966,000 after buying an additional 1,096 shares during the period. Exencial Wealth Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $333,000. RMR Wealth Builders lifted its holdings in Regeneron Pharmaceuticals by 15.7% in the 4th quarter. RMR Wealth Builders now owns 3,459 shares of the biopharmaceutical company’s stock worth $2,670,000 after buying an additional 470 shares during the period. Finally, Anchyra Partners LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $299,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.7%

REGN stock opened at $731.77 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The business’s 50 day moving average price is $760.43 and its two-hundred day moving average price is $735.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The company has a market capitalization of $77.36 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $12.07 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,774 shares of company stock valued at $2,942,738 in the last ninety days. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on REGN shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Evercore upped their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Finally, Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $825.35.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.